Selective HDAC8 Degraders for Off-Target Toxicity Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing HDAC inhibitors have a narrow therapeutic window and cause adverse side effects due to off-target toxicity from binding to unintended HDAC isoforms, necessitating the development of compounds that selectively target HDAC8 for treating diseases like cancer and neurodegenerative diseases.

Innovation Solution

Development of compounds represented by formula (I) that selectively degrade HDAC8 through a degron-based mechanism, minimizing off-target effects on other HDAC isoforms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If HDAC inhibitors are used to treat diseases, then therapeutic effect is improved, but off-target toxicity increases causing adverse side effects

Engineering Contradiction:

Improvetherapeutic effectVSAvoidoff-target toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The HDAC inhibitor class is segmented into isoform-specific compounds. The patent develops compounds that selectively target HDAC8 while sparing other HDAC isoforms, dividing the broad-spectrum inhibition approach into targeted, isoform-specific inhibition to reduce off-target effects

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by designing compounds with specific molecular structures that confer selectivity for HDAC8. The compounds have distinct structural features (such as specific substituent patterns on the heteroaryl ring) that match the unique binding pocket characteristics of HDAC8, allowing selective inhibition at the molecular level

Inventive Principle:

Principle #3Local quality

2Adaptability or versatility

If broad-spectrum HDAC inhibition is achieved, then therapeutic coverage is improved, but selectivity decreases leading to narrow therapeutic window

Engineering Contradiction:

Improvetherapeutic coverageVSAvoidselectivity

Core Design Contradiction:

Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

Instead of designing broad-spectrum inhibitors and hoping for selectivity, the patent inverts the approach by designing compounds from the outset to be highly selective for a single isoform (HDAC8). The therapeutic coverage is achieved through isoform-specific mechanisms rather than pan-HDAC inhibition

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS20250387491A1Selective histone deacetylase 8 (HDAC8) degraders and methods of use thereof

Publication Date: 2025.12.25 DANA FARBER CANCER INSTITUTE INC

AI summary

The present disclosure relates to compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylase 8 (HDAC8) activity. The compounds disclosed comprise HDAC8 Targeting Ligand TL moiety covalently linked to a Dergon moiety recruiting E3 ubiquitin ligase to HDAC8. In some embodiments, the degron may bind the E3 ligase which is von Rippel-Lindau (VHL) tumor suppressor.